FDA's RSABE on NTIDs in R [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2018-03-02 00:39 (2629 d 22:49 ago) – Posting: # 18492
Views: 14,852

Dear CECIF,

❝ Now, If I understand correctly this is bioequivalent because:


❝ 1. 95% CI of RSABE criterion= -0.009828289 <0


Correct.

❝ 2. Conventional ABE test: 0.9 < 0.9429483, 1.11>1.029172 (or is it also with conventional limits 0.8 and 1.25?).


As Detlew already pointed out: 80–125%. See the guidance:

Use the unscaled average bioequivalence procedure to determine BE for individual PK parameter(s). […] should pass […] also regular unscaled bioequivalence limits of 80.00-125.00%.


❝ 3. Upper 90% CI of the ratio swT/swR: 0.6842668<=2.5


Correct.

❝ In addition to this, do I still have to demonstrate conventional bioequivalence for:

❝ ❝ 1. Period 1 vs period 2 (regular bioequivalence study)

❝ ❝ 2. Period 3 vs period 4 (replicated study)

❝ ❝ 3. Pooled analysis (Average periods 1 and 3 vs average period 2 and 4)

❝ ?

❝ as they do here? https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40301_Warfarin%20Sodium_Approv.pdf


Again, as Detlew wrote: No.
BTW, I don’t see such a (strange) requirement in the ANDA of 1999 (!) you linked.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
128 visitors (0 registered, 128 guests [including 6 identified bots]).
Forum time: 00:29 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5